Bank Of America Hikes Pfizer Price Target, Estimates Citing Orphan Drug Catalysts

Large-cap pharma stocks have seen a mixed performance in year to date, and among this group, Pfizer Inc. PFE is poised to benefit from some key second-half catalysts, according to an analyst at Bank of America Merrill Lynch.

The Analyst

Jason Gerberry reiterated a Buy rating on Pfizer and raised the price target from $45 to $48, attributing the revision to higher estimates, with double-digit EPS growth in the 2020-2023 timeframe and pipeline optionality.

The Thesis

Pfizer may soon transform from being a fringe player in the orphan drugs to a mainstream company, given three upcoming catalysts in the segment, Gerberry said in a note.

The analyst sees the Vyndaqel launch in cardiomyopathy as a catalyst, citing bullish feedback of KOL physicians on immediate conversion of existing U.S. patients. Long-term orphan drug launch analysis suggests scope for market expansion and in turn upside to BofA's above-consensus forecast, the analyst added. Gerberry estimates peak sales of $2 billion for the drug.

Gerberry also sees upside optionality in DMD gene therapy candidate ‘9926 for which a Phase 1 data readout is scheduled for mid-2019. If the data is positive, the analyst said, Pfizer can directly launch a Phase 3 trial by year-end 2019, same as the timeline for the lead competitor Sarepta Therapeutics Inc SRPT.

The analyst said the Phase 3 data for rivipansel in Phase 3 sickle cell anemia is likely to be the third catalyst.

Collectively, the three catalysts could lead to 3-6 percent valuation upside and possible re-rate on validation of orphan pipeline.

Price Action

Pfizer's stock traded around $42.84 per share at time of publication.

Related Links:

6 Gene Therapy M&A Targets On The Radar

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorLong IdeasPrice TargetAnalyst RatingsTrading IdeasBank of AmericaJason GerberryRivipanselVyndaqel
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!